[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cullinan Therapeutics Inc (CGEM)

Cullinan Therapeutics Inc (CGEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 943,995
  • Shares Outstanding, K 61,458
  • Annual Sales, $ 0 K
  • Annual Income, $ -219,880 K
  • EBIT $ -240 M
  • EBITDA $ -240 M
  • 60-Month Beta -0.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.60

Options Overview Details

View History
  • Implied Volatility 160.19% (+3.95%)
  • Historical Volatility 70.77%
  • IV Percentile 40%
  • IV Rank 14.78%
  • IV High 740.76% on 09/19/25
  • IV Low 59.52% on 08/18/25
  • Expected Move (DTE 20) 4.47 (28.00%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 107
  • Volume Avg (30-Day) 177
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 6,228
  • Open Int (30-Day) 5,243
  • Expected Range 11.50 to 20.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.76
  • Number of Estimates 7
  • High Estimate $-0.26
  • Low Estimate $-1.01
  • Prior Year $-1.07
  • Growth Rate Est. (year over year) +28.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.67 +27.86%
on 04/30/26
16.68 -2.88%
on 05/27/26
+3.35 (+26.07%)
since 04/29/26
3-Month
12.40 +30.64%
on 03/24/26
16.68 -2.88%
on 05/27/26
+0.70 (+4.52%)
since 02/27/26
52-Week
5.68 +185.21%
on 10/03/25
16.74 -3.23%
on 02/27/26
+8.36 (+106.63%)
since 05/28/25

Most Recent Stories

More News
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies  Initial data from the first multi-dose cohort...

CGEM : 16.35 (+6.45%)
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan...

CGEM : 16.35 (+6.45%)
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.  (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact...

CGEM : 16.35 (+6.45%)
The Biology Came First.

Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth...

CGEM : 16.35 (+6.45%)
IDXX : 563.85 (-0.74%)
IPA : 2.07 (+7.25%)
ARGX : 837.31 (-0.14%)
XNCR : 11.97 (-0.29%)
HYFT : 1.7500 (-2.23%)
Cullinan Therapeutics: Q1 Earnings Snapshot

Cullinan Therapeutics: Q1 Earnings Snapshot

CGEM : 16.35 (+6.45%)
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026  Zipalertinib NDA for...

CGEM : 16.35 (+6.45%)
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

NDA submission based on the Phase 2b REZILIENT1 clinical trial, which demonstrated clinically meaningful and durable responses in patients with relapsed EGFR exon 20 insertion–mutated NSCLC ...

CGEM : 16.35 (+6.45%)
Cullinan Therapeutics: Q4 Earnings Snapshot

Cullinan Therapeutics: Q4 Earnings Snapshot

CGEM : 16.35 (+6.45%)
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline...

CGEM : 16.35 (+6.45%)
Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class,...

CGEM : 16.35 (+6.45%)

Business Summary

Cullinan Therapeutics Inc. is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. The company's product pipeline consists CLN-978. Cullinan Therapeutics Inc., formerly known as Cullinan Oncology Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 16.70
2nd Resistance Point 16.23
1st Resistance Point 15.79
Last Price 16.35
1st Support Level 14.88
2nd Support Level 14.41
3rd Support Level 13.97

See More

52-Week High 16.74
Last Price 16.35
Fibonacci 61.8% 12.52
Fibonacci 50% 11.21
Fibonacci 38.2% 9.90
52-Week Low 5.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.